Next-gen leaders are revitalizing India’s pharmaceutical landscape as family-run drug empires successfully navigate leadership transitions.
India's largest pharmaceutical companies, such as Sun Pharmaceutical Industries Ltd and Torrent Pharmaceuticals Ltd, are preparing the next generation of their promoter families to take over the reins. Recently, Torrent Pharma announced the appointment of Aman Mehta,...
Pfizer-Arvinas treatment outperforms AstraZeneca’s in slowing breast cancer progression.
A promising experimental treatment for breast cancer, developed by Pfizer and Arvinas, has shown significant results in delaying the progression of the disease. The treatment, called vepdegestrant, was tested in a clinical trial of 624 patients with a specific type of...
The US Food and Drug Administration has issued a single observation for Cipla’s Bommasandra manufacturing facility.
The US Food and Drug Administration (USFDA) has issued a single observation for Cipla's Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the facility...
Pfizer, AstraZeneca, and Daiichi Sankyo unveil groundbreaking cancer treatment findings at the 2025 ASCO Annual Meeting, as reported on geneonline.com.
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured significant presentations from major pharmaceutical companies, including Pfizer, AstraZeneca, and Daiichi Sankyo. The meeting highlighted new data on innovative cancer treatments, showcasing...
A 68-year-old woman undergoes successful Reverse Total Shoulder Replacement Surgery at Fortis Hospital Nagarbhavi
A 68-year-old woman, Mrs. Basanti, was successfully treated for severe shoulder arthritis at Fortis Hospital Nagarbhavi in Bangalore. She had been suffering from intense pain and limited mobility in her right shoulder for over two years, which affected her daily...
Piramal Pharma Boosts Biologics Production Capacity to Accelerate New Medicine Development – geneonline.com
Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to enhance its drug development capabilities. This strategic move is aimed at strengthening the company's position in the...
Pfizer’s Oral Obesity Medication Failure: A Sign of Underlying Issues in the Company’s Pipeline – Seeking Alpha
Pfizer's recent failure to gain FDA approval for its oral obesity drug, danuglipron, has raised concerns about the company's research and development pipeline. Danuglipron was expected to be a major contributor to Pfizer's revenue growth, but its rejection by the FDA...
Natco Pharma’s Q4 net profit sees 5% year-over-year increase, reaching ₹406 crore.
Natco Pharma Ltd, an Indian multinational pharmaceutical company, reported a 5% increase in consolidated net profit for the quarter ended March 31, 2025, with a net profit of ₹406 crore compared to ₹386.3 crore in the same period last year. The company's quarterly...
Next-gen leaders are revitalizing India’s pharmaceutical landscape as family-run drug empires successfully navigate leadership transitions.
India's largest pharmaceutical companies, such as Sun Pharmaceutical Industries Ltd and Torrent Pharmaceuticals Ltd, are preparing the next generation of their promoter families to take over the reins. Recently, Torrent Pharma announced the appointment of Aman Mehta,...
Sun Pharmaceutical Industries receives US FDA approval for cutting-edge skin treatment device.
Sun Pharmaceutical Industries has received approval from the US Food and Drug Administration (FDA) for a new medical device designed to treat actinic keratoses (AK), a skin condition caused by prolonged sun exposure. AK is characterized by the appearance of red, rough...
Nomura Warns: Trump’s Drug Pricing Order Could Have Significant Impact on Sun Pharma
The pharmaceutical sector is facing uncertainty after US President Donald Trump signed an executive order on May 12, requiring US drug companies to align their prices with those in other developed countries. This move could have a significant negative impact on the...
Sun Pharmaceuticals unveils its first-ever corporate brand initiative in the Indian market
Sun Pharmaceutical Industries (Sun Pharma) has launched a corporate brand campaign titled "Touching 1,000 Lives Every Minute" to highlight its role in supporting patients, caregivers, doctors, pharmacists, and communities. The campaign showcases the company's...
Sun Pharma appoints Jayashree Satagopan as its new Chief Financial Officer
Sun Pharmaceutical Industries Ltd. is a prominent player in the Indian pharmaceutical industry. The company's product portfolio is diverse, with a focus on generic and over-the-counter (OTC) medicines, which account for approximately 94% of its net sales. These...
Dilip Shanghvi’s fearless approach to risk has propelled Sun Pharma to great heights, and his entrepreneurial spirit shows no signs of slowing down.
Dilip Shanghvi, the 69-year-old chairman and managing director of Sun Pharma, India's largest pharmaceutical company, reflects on his 42-year journey of building the company from scratch. With a current market capitalization of ₹410,670 crore and a net cash position...
Sun Pharma’s MM-II trial demonstrates sustained pain relief for patients with knee osteoarthritis.
Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company, has announced promising results from a clinical trial for MM-II, a new non-opioid therapy for knee osteoarthritis pain relief. The trial, conducted in partnership with Moebius Medical,...
Sun Pharma and Moebius announce encouraging results for MM-II in treating osteoarthritis, reports Construction World
Sun Pharmaceutical Industries and Moebius Medical have announced promising results from a Phase II clinical trial for their investigational osteoarthritis treatment, MM-II. The study demonstrated significant improvements in pain reduction and functional improvement in...
Natco Pharma’s Q4 net profit sees 5% year-over-year increase, reaching ₹406 crore.
Natco Pharma Ltd, an Indian multinational pharmaceutical company, reported a 5% increase in consolidated net profit for the quarter ended March 31, 2025, with a net profit of ₹406 crore compared to ₹386.3 crore in the same period last year. The company's quarterly...
Divis Laboratories signs long-term manufacturing and supply pact with international pharmaceutical company.
Divis Laboratories has secured a long-term manufacturing and supply agreement with a global pharmaceutical company. Under the terms of the agreement, Divis will manufacture and supply advanced intermediates to the pharma company, with the details of the commercial...
Unlocking the Emerging Opportunities in India’s Pharmaceutical Industry
The Indian pharmaceutical sector has demonstrated robust growth over the past year, driven by a new trade agreement with the European Union that reduces tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic...
SMA patients welcome Natco’s development of a generic drug, calling on the government to ensure timely access to it.
The article reports on the recent development of a generic drug by Natco Pharmaceuticals, a leading Indian pharmaceutical company, which is expected to benefit patients suffering from Spinal Muscular Atrophy (SMA). SMA is a genetic disorder that affects the muscles,...
Patents for Pharmaceuticals: Balancing Exclusive Rights with Public Welfare
The Indian court, Justice Mini Pushkarna, recently ruled against granting an injunction in favor of Roche, a pharmaceutical company, in a landmark case involving the patent dispute over the drug Risdiplam, used to treat Spinal Muscular Atrophy (SMA). The court's...
Natco Pharma’s Executive Vice President of Technology Transfer, Intellectual Property Rights and Regulatory Affairs, Dr Ramesh Dandala, retires.
A Senior Executive at Natco Pharma Retires Natco Pharma, a leading Indian pharmaceutical company, has announced the superannuation of Dr. Ramesh Dandala, the Executive Vice President of Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API). Dr....
Citi cites low risk of US tariffs on Indian pharma, favoring Torrent Pharma and Divi’s.
Citibank has analyzed the potential impact of US tariffs on Indian pharmaceutical companies and has assigned a low probability to such an event. The brokerage firm simulated a 10% tariff scenario and found that companies with a high exposure to US generics, such as...
Delhi High Court orders Natco Pharma to put risk of launching novel spinal medication Risdiplam on hold in light of patent infringement controversy.
The Delhi High Court has ordered Natco Pharma to pause the launch of a generic version of Roche's rare disease drug, Risdiplam, amid a patent dispute. The court has restrained Natco Pharma from launching the generic version of the drug, which is used to treat spinal...
Next-gen leaders are revitalizing India’s pharmaceutical landscape as family-run drug empires successfully navigate leadership transitions.
India's largest pharmaceutical companies, such as Sun Pharmaceutical Industries Ltd and Torrent Pharmaceuticals Ltd, are preparing the next generation of their promoter families to take over the reins. Recently, Torrent Pharma announced the appointment of Aman Mehta,...
Pfizer-Arvinas treatment outperforms AstraZeneca’s in slowing breast cancer progression.
A promising experimental treatment for breast cancer, developed by Pfizer and Arvinas, has shown significant results in delaying the progression of the disease. The treatment, called vepdegestrant, was tested in a clinical trial of 624 patients with a specific type of...
The US Food and Drug Administration has issued a single observation for Cipla’s Bommasandra manufacturing facility.
The US Food and Drug Administration (USFDA) has issued a single observation for Cipla's Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the facility...
Pfizer, AstraZeneca, and Daiichi Sankyo unveil groundbreaking cancer treatment findings at the 2025 ASCO Annual Meeting, as reported on geneonline.com.
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured significant presentations from major pharmaceutical companies, including Pfizer, AstraZeneca, and Daiichi Sankyo. The meeting highlighted new data on innovative cancer treatments, showcasing...
A 68-year-old woman undergoes successful Reverse Total Shoulder Replacement Surgery at Fortis Hospital Nagarbhavi
A 68-year-old woman, Mrs. Basanti, was successfully treated for severe shoulder arthritis at Fortis Hospital Nagarbhavi in Bangalore. She had been suffering from intense pain and limited mobility in her right shoulder for over two years, which affected her daily...
Piramal Pharma Boosts Biologics Production Capacity to Accelerate New Medicine Development – geneonline.com
Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to enhance its drug development capabilities. This strategic move is aimed at strengthening the company's position in the...
Pfizer’s Oral Obesity Medication Failure: A Sign of Underlying Issues in the Company’s Pipeline – Seeking Alpha
Pfizer's recent failure to gain FDA approval for its oral obesity drug, danuglipron, has raised concerns about the company's research and development pipeline. Danuglipron was expected to be a major contributor to Pfizer's revenue growth, but its rejection by the FDA...
Natco Pharma’s Q4 net profit sees 5% year-over-year increase, reaching ₹406 crore.
Natco Pharma Ltd, an Indian multinational pharmaceutical company, reported a 5% increase in consolidated net profit for the quarter ended March 31, 2025, with a net profit of ₹406 crore compared to ₹386.3 crore in the same period last year. The company's quarterly...
The US Food and Drug Administration has issued a single observation for Cipla’s Bommasandra manufacturing facility.
The US Food and Drug Administration (USFDA) has issued a single observation for Cipla's Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the facility...
Amit Patel has been promoted to lead Consumer Marketing Excellence as its new Head.
Amit Patel has been promoted to Head of Consumer Marketing Excellence at Cipla India, a leading pharmaceutical company. In his new role, Patel will be responsible for driving consumer marketing across various therapeutic areas, with a focus on building patient-centric...
The Indian market for active pharmaceutical ingredients has experienced significant revenue generation.
The India Active Pharmaceutical Ingredients (API) market is expected to experience significant growth, with an estimated value of USD 14.81 billion in 2025 and a projected value of USD 25.23 billion by 2032, at a compound annual growth rate (CAGR) of 7.9%. This growth...
Cipla Limited and its division EMEU, have been honoured at the prestigious Healthcare Asia Pharma Awards 2025.
Cipla EMEU and Cipla Limited have been recognized at the Healthcare Asia Pharma Awards 2025 for their innovative initiatives. Cipla EMEU received the ESG Program of the Year - India award for its Ahead & Apart campaign, which promotes sustainable practices in the...
Cipla to Report Q4 FY 2025 Earnings on May 13, Dividend Payment Possible
Pharmaceutical company Cipla has announced the date for its earnings release for the fourth quarter and full year ended March 31, 2025. The company's Board of Directors is scheduled to meet on Tuesday, May 13, 2025, to consider and approve the standalone and...
A sudden surge in demand for Doxorubicin may send market momentum soaring, with influential companies like Merck & Co., Lupin, and Cipla playing a pivotal role.
The latest survey on the Doxorubicin market has been conducted to provide a comprehensive analysis of the market's performance, competitive environment, and market size. The report covers the period from 2019 to 2024 and provides a forecast till 2031. The market size...
Cipla Lacrosse up a massive partnership with Formosa, securing a sweeping deal spanning 11 countries for their clobetasol offerings.
Cipla, a leading global pharmaceutical company, has signed an exclusive licensing agreement to expand its ophthalmology portfolio and global offerings. The agreement involves the acquisition of Formosa Pharmaceuticals' US FDA-approved clobetasol propionate 0.05%...
Eli Lilly expands its global footprint by introducing Mounjaro, a groundbreaking weight management medication, to the Indian market.
Eli Lilly & Co. has launched its anti-obesity drug Mounjaro in India, making it the country's first treatment of its kind. The drug, which is used to treat obesity and type-2 diabetes, works by activating hormones that help reduce the amount of sugar in the blood and...
Apollo Hospitals Introduces ‘Fleet of Hope’ on World Emergency Medicine Day to Promote Awareness About 1066 Emergency Services
On World Emergency Medicine Day, Apollo Hospitals launched the "Fleet of Hope" initiative to raise awareness about its 1066 emergency services. The campaign aims to educate the public about the importance of emergency medical services and the role they play in saving...
Apollo Hospitals Sees Significant Increase in International Research Recognition
The Apollo Hospitals Group has made significant contributions to global healthcare research, as highlighted in a recent publication in the National Board of Examination Journal of Medical Sciences. The study, "Evaluating a Decade of Research Excellence: A Bibliometric...
Apollo introduces a revolutionary non-surgical treatment for piles, transforming patient care – Healthcare Radius
Apollo Hospitals has introduced a new non-surgical procedure to treat piles, also known as hemorrhoids. This innovative treatment offers a pain-free and minimally invasive solution for patients suffering from this common condition. Piles are swollen blood vessels in...
Meet the 92-year-old entrepreneur who has amassed a staggering net worth of Rs 27,500 crore, owning an impressive 71 hospitals and 5000 pharmacies, and still reports to his office every day.
Meet Dr. Prathap C. Reddy, a 92-year-old cardiologist and founder of the Apollo Hospitals chain, a multinational hospital network headquartered in Chennai, India. With a net worth of approximately Rs 27,500 crore, Dr. Reddy is a remarkable individual who has dedicated...
Dr. Rooma Sinha from Apollo achieves milestone of over 1,000 robotic surgeries for benign gynecological conditions.
Dr. Rooma Sinha, a renowned gynecologist at Apollo Hospitals, has achieved a remarkable milestone by completing over 1,000 robotic surgeries for benign gynecological conditions. This feat is a testament to her exceptional skills and expertise in the field of robotic...
Discover the 92-year-old visionary who founded 71 hospitals and 5000 pharmacies, driven by a pivotal incident, and learn the remarkable story of…
Dr. Prathap C Reddy, the 92-year-old founder of Apollo Hospitals, is a shining example of dedication and passion. Despite his advanced age, he continues to work full-time, arriving at his office at 10 am sharp and working until 5 pm, six days a week. His commitment to...
Apollo Hospitals Group Pays Tribute to Its Care Champions on International Nurses Day
Apollo Hospitals celebrated International Nurses Day on May 12, 2025, with a week-long series of events to recognize the vital role nurses play in global health systems and economic resilience. The celebrations, which took place across the Apollo Hospitals network,...
Hyderabad-based gynaecologist completes over 1,000 robotic surgeries
A significant milestone has been achieved in the field of gynecological surgery at Apollo Hospitals in Hyderabad. Dr. Rooma Sinha, a Senior Consultant in Gynaecology and Robotic Surgery, has successfully completed over 1,000 robotic procedures for benign gynecological...
Pfizer-Arvinas treatment outperforms AstraZeneca’s in slowing breast cancer progression.
A promising experimental treatment for breast cancer, developed by Pfizer and Arvinas, has shown significant results in delaying the progression of the disease. The treatment, called vepdegestrant, was tested in a clinical trial of 624 patients with a specific type of...
Pfizer, AstraZeneca, and Daiichi Sankyo unveil groundbreaking cancer treatment findings at the 2025 ASCO Annual Meeting, as reported on geneonline.com.
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured significant presentations from major pharmaceutical companies, including Pfizer, AstraZeneca, and Daiichi Sankyo. The meeting highlighted new data on innovative cancer treatments, showcasing...
Pfizer’s Oral Obesity Medication Failure: A Sign of Underlying Issues in the Company’s Pipeline – Seeking Alpha
Pfizer's recent failure to gain FDA approval for its oral obesity drug, danuglipron, has raised concerns about the company's research and development pipeline. Danuglipron was expected to be a major contributor to Pfizer's revenue growth, but its rejection by the FDA...
The market for Anti-CD20 Monoclonal Antibodies (MAbs) is experiencing exponential growth, with key players like Pfizer, Teva, and Aptevo driving the trend.
The Global Anti-CD20 Monoclonal Antibodies (MAbs) Market study, conducted by USD Analytics, provides a comprehensive analysis of the market, covering over 143 pages. The report describes the product and industry scope, market prognosis, and status for 2025-2034. The...
Xtandi, a medication developed by Astellas and Pfizer, has been shown to decrease mortality risk in a clinical trial involving prostate cancer patients.
Astellas and Pfizer have released five-year follow-up results from the open-label extension of the Phase III ARCHES trial, which evaluated the effectiveness of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) in men with metastatic...
SK bioscience wins Pfizer vaccine patent case: Investing.com India reports
South Korea's SK bioscience has emerged victorious in a patent lawsuit against Pfizer, concerning the pneumococcal vaccine. The company won the backing of the Korean Supreme Court, bringing an end to the long-standing dispute. The court's decision confirms that SK...
Mankind Pharma appoints Dapinder Singh Narula as new Head of Talent Management, reports People Matters.
Dapinder Singh Narula has been appointed to lead the Talent Management function at Mankind Pharma, a leading Indian pharmaceutical company. In this exclusive interview with People Matters, Narula shared his vision and strategies for talent management in the...
Earnings Alert: Upcoming Q4 Results Include ITC, Hindalco, Pfizer, Power Grid, IndusInd Bank, RVNL, JSW Steel, and Others on Goodreturns
Next week is expected to be a busy one for corporate earnings, with several major companies set to announce their Q4 results. The list of companies includes ITC, Hindalco, Pfizer, Power Grid, IndusInd Bank, RVNL, and JSW Steel, among others. ITC, one of India's...
A 68-year-old woman undergoes successful Reverse Total Shoulder Replacement Surgery at Fortis Hospital Nagarbhavi
A 68-year-old woman, Mrs. Basanti, was successfully treated for severe shoulder arthritis at Fortis Hospital Nagarbhavi in Bangalore. She had been suffering from intense pain and limited mobility in her right shoulder for over two years, which affected her daily...
Fortis Hospital hosts interactive session with village heads to boost rural family health awareness
Fortis Hospital in Ludhiana, Punjab, recently organized a meeting with sarpanches (village heads) from Ludhiana and surrounding villages. The event aimed to build stronger partnerships with the community and raise awareness about the importance of family health,...
Jackie Shroff Lends Support to Fortis’ ‘Red Run to End Thalassemia’ Awareness Campaign!
Bollywood actor Jackie Shroff has once again taken on the role of Brand Ambassador for a nationwide movement to eliminate Thalassemia from India by 2035. The initiative, #RedRuntoEndThalassemia, was launched by Fortis Memorial Research Institute, Gurugram, and aims to...
A 210-kg individual successfully undergoes robotic-assisted bariatric surgery at Fortis Hospital in Mohali.
A 210-kilogram man recently underwent a successful robot-aided bariatric surgery at Fortis Hospital in Mohali. The patient, who wishes to remain anonymous, was experiencing significant health complications due to his weight, including diabetes, high blood pressure,...
FMRI, Gurugram Introduces ‘Two-Minute Oral Cancer Prevention Initiative’
April is Oral Cancer Awareness Month, and to mark this occasion, Fortis Memorial Research Institute, Gurugram, has launched a campaign titled "Two-Minute Action for Oral Cancer Protection" under the hashtag #ActAgainstOralCancer. The campaign aims to address the...
Yemeni Woman, 63, Regains Mobility After 5-Year Struggle, Thanks to Successful Robot-Assisted Bilateral Knee Replacement Surgery at Fortis Bannerghatta – APN News
A 63-year-old woman from Yemen has successfully undergone a robot-assisted bilateral knee replacement surgery at Fortis Hospital, Bannerghatta, in Bengaluru, India. The surgery has enabled her to regain mobility after being bedridden for five years due to severe knee...
Fortis Hospital Mohali hosts symposium on colorectal cancer to encourage mass screening
Fortis Hospital Mohali recently organized a symposium on colorectal cancer, which drew over 130 delegates, including leading experts in the field of colorectal cancer surgery and oncology. The event aimed to educate healthcare professionals about the risk factors,...
Fortis Healthcare hosts a symposium to promote awareness about colorectal cancer prevention and treatment.
Fortis Cancer Institute in Mohali recently hosted a national symposium on colorectal cancer, aiming to raise awareness about the prevention and early detection of this preventable yet deadly disease. The event drew over 130 delegates, including leading oncologists and...